• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Xu Diyong

    6/16/26 4:30:23 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QTTB alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Xu Diyong

    (Last)(First)(Middle)
    Q32 BIO INC.
    830 WINTER STREET

    (Street)
    WALTHAM MASSACHUSETTS 02451

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Q32 Bio Inc. [ QTTB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirectorX10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/12/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (Right to Buy)$12.6406/12/2026A9,810 (1)06/11/2036Common Stock9,810$09,810D(2)
    Explanation of Responses:
    1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
    2. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.
    /s/ Eric Bell, Attorney-in-Fact06/16/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $QTTB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QTTB

    DatePrice TargetRatingAnalyst
    5/18/2026Overweight
    Cantor Fitzgerald
    2/25/2026$13.00Buy
    H.C. Wainwright
    2/11/2025$22.00 → $3.00Outperform → Market Perform
    BMO Capital Markets
    2/11/2025$20.00 → $4.00Overweight → Neutral
    Piper Sandler
    12/11/2024Buy → Neutral
    Guggenheim
    12/11/2024$95.00 → $16.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$90.00 → $22.00Strong Buy → Outperform
    Raymond James
    12/11/2024$68.00 → $9.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $QTTB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Violette Shelia M. was granted 37,500 shares, increasing direct ownership by 40% to 130,569 units (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    7/20/26 9:31:18 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Morrison Jodie Pope was granted 132,000 shares, increasing direct ownership by 60% to 353,104 units (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    7/20/26 9:27:42 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO and President Kalowski Lee was granted 53,250 shares, increasing direct ownership by 60% to 142,443 units (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    7/20/26 9:25:35 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Q32 Bio Inc.

    SCHEDULE 13D/A - Q32 Bio Inc. (0001661998) (Subject)

    7/20/26 9:32:47 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Q32 Bio Inc.

    S-3 - Q32 Bio Inc. (0001661998) (Filer)

    7/17/26 4:14:39 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Q32 Bio Inc.

    8-K - Q32 Bio Inc. (0001661998) (Filer)

    7/15/26 5:18:59 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Q32 Bio

    Cantor Fitzgerald initiated coverage of Q32 Bio with a rating of Overweight

    5/18/26 8:36:12 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Q32 Bio with a new price target

    H.C. Wainwright initiated coverage of Q32 Bio with a rating of Buy and set a new price target of $13.00

    2/25/26 7:53:48 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Q32 Bio from Outperform to Market Perform and set a new price target of $3.00 from $22.00 previously

    2/11/25 7:55:03 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $QTTB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

    WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten public offering of 6,027,399 shares of its common stock at a public offering price of $18.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 4,931,506 shares of its common stock at a public offering price of $18.2499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-fu

    7/14/26 10:58:00 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

    WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Q32 Bio intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissio

    7/13/26 4:01:00 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

    -- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis ---- 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis and 30.3% of patients achieved SALT-20 response at Week 36 in the ITT analysis of all enrolled patients ---- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals ---- Bempikibart demonstrated a favorable PK, PD and ADA profile -- -- Data supports further development of bempikibart in alopecia areata; Company intends to advance a registration-directed program in the first half of 2027 ---- Q32

    7/13/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Xu Diyong bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    6/1/26 9:15:32 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    6/1/26 9:13:02 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

    SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

    11/14/24 5:46:10 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Q32 Bio Inc.

    SC 13G - Q32 Bio Inc. (0001661998) (Subject)

    11/13/24 4:05:13 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

    SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

    10/25/24 6:06:25 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Financials

    Live finance-specific insights

    View All

    Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

    -- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis ---- 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis and 30.3% of patients achieved SALT-20 response at Week 36 in the ITT analysis of all enrolled patients ---- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals ---- Bempikibart demonstrated a favorable PK, PD and ADA profile -- -- Data supports further development of bempikibart in alopecia areata; Company intends to advance a registration-directed program in the first half of 2027 ---- Q32

    7/13/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026

    -- Conference call to be held Monday, July 13th at 8:00 a.m. E.T. --WALTHAM, Mass., July 10, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA on Monday, July 13, 2026. Following the announcement, Q32 Bio will host a conference call and webcast at 8:00 a.m. E.T. on Monday, July 13, 2026 to discuss the results.Conference CallQ32 Bio's live conference call an

    7/10/26 4:05:00 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

    WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25th Annual Needham Virtual Healthcare Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. An archived replay will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targets potent

    4/8/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care